Shrinks In Sneakers

Tag: life style modiification

  • Adult ADHD: Current Trends and Emerging Research (2025 Update)

    Adult ADHD: Current Trends and Emerging Research (2025 Update)

    Attention-deficit/hyperactivity disorder (ADHD) has traditionally been seen as a childhood condition — but in recent years, there has been an explosion of interest in ADHD among adults. As awareness grows, so does research. New studies are reshaping how we diagnose, treat, and understand ADHD in the adult population.

    1. 🔥 Rising Rates of Adult ADHD Diagnosis

    Recent studies show that adult ADHD diagnoses have sharply increased over the past decade. According to a 2023 analysis published in JAMA Psychiatry, the diagnosis rate for adults aged 18–45 rose by more than 80% between 2011 and 2022.

    Why the surge?

    • Greater public awareness
    • Better screening tools for adults
    • A cultural shift toward recognizing executive dysfunction in adulthood

    However, there are concerns that overdiagnosis is also happening, particularly when ADHD is diagnosed after brief evaluations without thorough history-taking.

    2. 🧠 Expanded Understanding of Adult ADHD Symptoms

    The symptom profile in adults differs significantly from children. While hyperactivity often fades, issues like emotional dysregulation, disorganization, and executive dysfunction persist.

    Recent research emphasizes that adult ADHD often presents as:

    • Chronic procrastination
    • Low frustration tolerance
    • Difficulty managing responsibilities (work, home, finances)
    • Persistent inner restlessness

    A 2024 review in The American Journal of Psychiatry noted that emotional impulsivity may actually be a core symptomin adults, not just a secondary feature.

    3. đź’Š Treatment Shifts: Caution Around Stimulants

    While stimulant medications (like amphetamines and methylphenidate) remain the gold standard, new studies highlight the importance of careful prescribing, especially in adults with:

    • Comorbid substance use disorders
    • Cardiovascular risk factors
    • Poor diagnostic workups

    Non-stimulant treatments are gaining ground:

    • Atomoxetine (Strattera) remains a mainstay.
    • Viloxazine (Qelbree) was approved for adult ADHD in 2024 and shows promise with lower abuse potential.
    • Bupropion (Wellbutrin) continues to be an important off-label option, especially when depression coexists with ADHD.

    According to a 2024 meta-analysis in Lancet Psychiatry, non-stimulants now account for about 30% of new ADHD prescriptions in adults â€” a significant jump compared to previous years.

    4. 🧬 Precision Psychiatry and Biomarkers on the Horizon

    Emerging studies are exploring neuroimaging and genetic markers to better understand adult ADHD subtypes.

    • A 2023 study using fMRI found distinct prefrontal cortex dysfunction patterns in adults with ADHD compared to controls.
    • Genetic research continues to implicate genes related to dopamine transmission and synaptic plasticity.

    Although these findings are not yet ready for clinical application, the future of ADHD diagnosis may involve biomarkers, moving beyond subjective questionnaires alone.

    5. 🌿 Lifestyle Interventions Are Getting More Attention

    There’s a growing body of evidence supporting complementary approaches:

    • Cognitive-behavioral therapy (CBT) for ADHD-specific skills
    • Exercise as a way to enhance executive function and mood
    • Mindfulness practices to improve emotional regulation

    A 2024 RCT published in Behavior Therapy showed that an 8-week mindfulness-based intervention led to significant improvements in attention and working memory in adults with ADHD — with effect sizes comparable to pharmacotherapy in some cases.

    Final Thoughts

    Adult ADHD is real, complex, and often misunderstood.
    The field is evolving rapidly, with a push toward better diagnostics, safer treatments, and a broader understanding of how ADHD affects life across the lifespan.

    As research continues to grow, clinicians are challenged not only to treat ADHD effectively but to do so thoughtfully — avoiding both underdiagnosis and overdiagnosis.

    Stay tuned — the future of ADHD care is just getting started.

  • Metformin for Antipsychotic-Induced Weight Gain: What Took So Long?

    Metformin for Antipsychotic-Induced Weight Gain: What Took So Long?

    Antipsychotic-induced weight gain remains a significant challenge in psychiatric practice, contributing to metabolic syndrome, decreased quality of life, and reduced medication adherence. This issue is especially concerning given the chronic nature of psychiatric illnesses requiring antipsychotic treatment. Among strategies to address this, metformin—an insulin sensitizer primarily used for type 2 diabetes—has garnered considerable interest. Below, we summarize the evidence from randomized controlled trials (RCTs) evaluating metformin’s efficacy and safety in mitigating weight gain associated with antipsychotic medications.

    Evidence from Randomized Controlled Trials

    1. Meta-Analyses and Systematic Reviews
      • Multiple meta-analyses of RCTs have shown that metformin effectively reduces weight gain in individuals receiving antipsychotics. Weight reductions of 2-3 kg over 12-16 weeks have been reported compared to placebo.
      • Beyond weight loss, improvements in metabolic parameters such as fasting glucose, insulin resistance, and lipid profiles have been observed.
    2. Population-Specific Findings
      • First-Episode Psychosis (FEP): Studies indicate that metformin is particularly effective in individuals with FEP who experience rapid weight gain shortly after initiating antipsychotic therapy. Early intervention appears to yield more substantial benefits.
      • Chronic Schizophrenia: RCTs in populations with chronic schizophrenia have demonstrated similar weight-reducing effects, though results may be less pronounced compared to FEP patients.
    3. Adjunctive Lifestyle Interventions
      • Combining metformin with lifestyle interventions, such as diet and exercise counseling, results in synergistic benefits. RCTs demonstrate that this combination is more effective than metformin or lifestyle changes alone.

    Safety and Tolerability

    Metformin is generally well-tolerated. The most common side effects are gastrointestinal (e.g., nausea, diarrhea), which tend to subside with continued use. Rarely, lactic acidosis—a serious adverse event—can occur, particularly in individuals with renal impairment. It is crucial to monitor kidney function periodically.

    Practical Considerations

    1. Dosing: Initiate metformin at a low dose (e.g., 500 mg once daily) to minimize gastrointestinal side effects, and titrate gradually to a typical maintenance dose of 1,000-2,000 mg per day.
    2. Monitoring: Regularly assess weight, BMI, fasting glucose, and lipid profiles. Monitor renal function before and during treatment.
    3. Patient Selection: Metformin may be particularly beneficial for patients who:
      • Have significant weight gain or metabolic disturbances from antipsychotic use.
      • Are early in their antipsychotic treatment course.
      • Have no contraindications, such as severe renal impairment.

    Conclusion

    Metformin offers a promising strategy for mitigating antipsychotic-induced weight gain, supported by robust evidence from RCTs. While not a standalone solution, it can play a critical role in a comprehensive approach to managing the metabolic side effects of antipsychotics. Clinicians should consider metformin’s inclusion in treatment plans for patients struggling with weight gain or metabolic dysfunction related to antipsychotic treatment.